Cleveland BioLabs reorganises management as CEO Fonstein steps down
This article was originally published in Scrip
Executive Summary
Cancer drug discovery and development company Cleveland BioLabs has appointed its COO, Dr Yakov Kogan, interim CEO in addition to his current duties, following the resignation of Dr Michael Fonstein as CEO. Dr Fonstein will continue to serve as president of the company, while C Neil Lyons, Cleveland BioLabs' CFO, will add to his duties oversight of investor and public relations activities.